In the beginning of this year, I wrote two articles concerning torcetrapib, the $800 million failure of Pfizer to develop a new type of cholesterol medication. This novel medication called a CETP (cholesterol ester transfer protein) inhibitor is able to markedly raise HDL, but unfortunately was found to increase the risk of death. The increased risk of death was believed mainly due to an unexpected increase in blood pressure but there was some concern that the type of HDL produced may not be...


8 Restaurant Meals That Are Bad for Your Heart
10 Foods You Should Only Buy Organic
Triglycerides: Why They Matter and How to Lower Them
8 Foods That Lower Cholesterol